The European Commission did not cite any wrongdoing by specific companies in its preliminary report on 28 November 2008 into whether certain practices have stifled pharmaceutical innovation in Europe and/or prevented generic medicines from reaching the market in a timely fashion. However, enforcement action cannot be ruled out later, according to lawyers familiar with the investigation. This will only be known when the Commission issues its final report which is expected in late March or early April 2009.
